QQQ   357.86 (-1.83%)
AAPL   173.93 (-0.89%)
MSFT   319.53 (-0.39%)
META   295.73 (-1.31%)
GOOGL   130.44 (-2.47%)
AMZN   129.33 (-4.41%)
TSLA   255.70 (-2.62%)
NVDA   410.17 (-2.89%)
NIO   8.46 (-4.19%)
BABA   84.12 (-1.89%)
AMD   96.11 (-4.22%)
T   15.31 (-1.61%)
F   12.20 (-1.30%)
MU   67.90 (-2.55%)
CGC   0.77 (-11.53%)
GE   112.97 (-1.64%)
DIS   82.73 (+0.21%)
AMC   7.71 (-5.51%)
PFE   32.85 (-2.29%)
PYPL   58.62 (-3.68%)
NFLX   384.15 (-0.56%)
QQQ   357.86 (-1.83%)
AAPL   173.93 (-0.89%)
MSFT   319.53 (-0.39%)
META   295.73 (-1.31%)
GOOGL   130.44 (-2.47%)
AMZN   129.33 (-4.41%)
TSLA   255.70 (-2.62%)
NVDA   410.17 (-2.89%)
NIO   8.46 (-4.19%)
BABA   84.12 (-1.89%)
AMD   96.11 (-4.22%)
T   15.31 (-1.61%)
F   12.20 (-1.30%)
MU   67.90 (-2.55%)
CGC   0.77 (-11.53%)
GE   112.97 (-1.64%)
DIS   82.73 (+0.21%)
AMC   7.71 (-5.51%)
PFE   32.85 (-2.29%)
PYPL   58.62 (-3.68%)
NFLX   384.15 (-0.56%)
QQQ   357.86 (-1.83%)
AAPL   173.93 (-0.89%)
MSFT   319.53 (-0.39%)
META   295.73 (-1.31%)
GOOGL   130.44 (-2.47%)
AMZN   129.33 (-4.41%)
TSLA   255.70 (-2.62%)
NVDA   410.17 (-2.89%)
NIO   8.46 (-4.19%)
BABA   84.12 (-1.89%)
AMD   96.11 (-4.22%)
T   15.31 (-1.61%)
F   12.20 (-1.30%)
MU   67.90 (-2.55%)
CGC   0.77 (-11.53%)
GE   112.97 (-1.64%)
DIS   82.73 (+0.21%)
AMC   7.71 (-5.51%)
PFE   32.85 (-2.29%)
PYPL   58.62 (-3.68%)
NFLX   384.15 (-0.56%)
QQQ   357.86 (-1.83%)
AAPL   173.93 (-0.89%)
MSFT   319.53 (-0.39%)
META   295.73 (-1.31%)
GOOGL   130.44 (-2.47%)
AMZN   129.33 (-4.41%)
TSLA   255.70 (-2.62%)
NVDA   410.17 (-2.89%)
NIO   8.46 (-4.19%)
BABA   84.12 (-1.89%)
AMD   96.11 (-4.22%)
T   15.31 (-1.61%)
F   12.20 (-1.30%)
MU   67.90 (-2.55%)
CGC   0.77 (-11.53%)
GE   112.97 (-1.64%)
DIS   82.73 (+0.21%)
AMC   7.71 (-5.51%)
PFE   32.85 (-2.29%)
PYPL   58.62 (-3.68%)
NFLX   384.15 (-0.56%)
NASDAQ:SEEL

Seelos Therapeutics (SEEL) Competitors

$0.19
-0.12 (-38.71%)
(As of 09/21/2023 ET)
Compare
Today's Range
$0.19
$0.24
50-Day Range
$0.19
$1.64
52-Week Range
$0.19
$1.66
Volume
33.60 million shs
Average Volume
1.15 million shs
Market Capitalization
$24.30 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.33

SEEL vs. ANNX, CTXR, EVLO, BIVI, THRX, OPT, GNTA, ALT, RLMD, and APLT

Should you be buying Seelos Therapeutics stock or one of its competitors? The main competitors of Seelos Therapeutics include Annexon (ANNX), Citius Pharmaceuticals (CTXR), Evelo Biosciences (EVLO), BioVie (BIVI), Theseus Pharmaceuticals (THRX), Opthea (OPT), Genenta Science (GNTA), Altimmune (ALT), Relmada Therapeutics (RLMD), and Applied Therapeutics (APLT). These companies are all part of the "medical" sector.

Seelos Therapeutics vs.

Seelos Therapeutics (NASDAQ:SEEL) and Annexon (NASDAQ:ANNX) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, analyst recommendations, risk, valuation, institutional ownership, community ranking, earnings and media sentiment.

In the previous week, Seelos Therapeutics had 9 more articles in the media than Annexon. MarketBeat recorded 12 mentions for Seelos Therapeutics and 3 mentions for Annexon. Annexon's average media sentiment score of 0.66 beat Seelos Therapeutics' score of -0.73 indicating that Annexon is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Seelos Therapeutics
0 Very Positive mention(s)
4 Positive mention(s)
0 Neutral mention(s)
1 Negative mention(s)
4 Very Negative mention(s)
Negative
Annexon
2 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

18.0% of Seelos Therapeutics shares are owned by institutional investors. 6.4% of Seelos Therapeutics shares are owned by insiders. Comparatively, 19.1% of Annexon shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Seelos Therapeutics has a beta of 1.9, meaning that its stock price is 90% more volatile than the S&P 500. Comparatively, Annexon has a beta of 0.64, meaning that its stock price is 36% less volatile than the S&P 500.

Seelos Therapeutics presently has a consensus price target of $2.33, indicating a potential upside of 1,128.07%. Annexon has a consensus price target of $14.33, indicating a potential upside of 497.22%. Given Seelos Therapeutics' higher probable upside, analysts clearly believe Seelos Therapeutics is more favorable than Annexon.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Seelos Therapeutics
0 Sell rating(s)
2 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.33
Annexon
0 Sell rating(s)
2 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.60

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Seelos TherapeuticsN/AN/A-$73.53MN/AN/A
AnnexonN/AN/A-$141.95M-$1.98-1.21

Seelos Therapeutics received 45 more outperform votes than Annexon when rated by MarketBeat users. Likewise, 66.36% of users gave Seelos Therapeutics an outperform vote while only 61.90% of users gave Annexon an outperform vote.

CompanyUnderperformOutperform
Seelos TherapeuticsOutperform Votes
71
66.36%
Underperform Votes
36
33.64%
AnnexonOutperform Votes
26
61.90%
Underperform Votes
16
38.10%

Annexon's return on equity of -64.31% beat Seelos Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Seelos TherapeuticsN/A -10,287.49% -328.75%
Annexon N/A -64.31%-52.13%

Summary

Seelos Therapeutics beats Annexon on 7 of the 13 factors compared between the two stocks.


Get Seelos Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for SEEL and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SEEL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SEEL vs. The Competition

MetricSeelos TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$24.30M$5.14B$4.32B$6.27B
Dividend YieldN/A2.64%2.40%5.88%
P/E RatioN/A7.13137.6313.70
Price / SalesN/A156.202,812.6368.96
Price / CashN/A20.7387.40101.50
Price / Book-1.903.723.764.72
Net Income-$73.53M$178.51M$121.73M$185.68M
7 Day Performance-79.74%-5.08%-2.09%-3.31%
1 Month Performance-84.43%-5.93%-0.81%-4.40%
1 Year Performance-82.24%2.63%5.40%1.34%

Seelos Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ANNX
Annexon
2.0912 of 5 stars
$2.26
-4.2%
$14.00
+519.5%
-60.5%$120.32MN/A-1.1477Positive News
Gap Down
CTXR
Citius Pharmaceuticals
1.8325 of 5 stars
$0.78
-2.5%
$4.00
+412.3%
-44.8%$124.04MN/A-3.9021Gap Up
EVLO
Evelo Biosciences
2.2392 of 5 stars
$6.70
+2.9%
$63.33
+845.3%
-88.7%$126.19MN/A0.0066Options Volume
News Coverage
Positive News
Gap Down
BIVI
BioVie
1.8447 of 5 stars
$3.49
-3.3%
$10.33
+196.1%
+27.4%$128.45MN/A-2.2718News Coverage
Gap Down
THRX
Theseus Pharmaceuticals
2.05 of 5 stars
$2.96
-1.3%
$10.00
+237.8%
-56.4%$129.07MN/A-2.1038
OPT
Opthea
1.4995 of 5 stars
$2.26
-0.9%
$22.50
+895.6%
-69.9%$131.97M$108,406.000.002,021Analyst Report
GNTA
Genenta Science
2.1459 of 5 stars
$5.89
flat
$20.00
+239.6%
+5.5%$107.30MN/A0.004Gap Up
ALT
Altimmune
2.0248 of 5 stars
$2.61
+7.4%
$17.00
+551.3%
-78.6%$137.51M$-81,000.00-1.6052News Coverage
RLMD
Relmada Therapeutics
2.4681 of 5 stars
$3.39
-1.2%
$10.80
+219.1%
-90.8%$101.89MN/A-0.7914News Coverage
APLT
Applied Therapeutics
2.1673 of 5 stars
$1.60
-5.9%
$9.50
+493.8%
+142.7%$100.99MN/A-1.4422Gap Down

Related Companies and Tools

This page (NASDAQ:SEEL) was last updated on 9/21/2023 by MarketBeat.com Staff

My Account -